Roivant Sciences：通过Vants子公司实现生物技术细分领域的多元布局（纳斯达克：ROIV）
· seekingalpha.com
Roivant Sciences展望：LISRAYA获批增强营收，而brepocitinib和mosliciguat可能扩展免疫学/肺部药物系列。点击了解更多关于ROIV股票的信息。
Roivant Sciences Ltd. ( ROIV ) is a clinical- and commercial-stage biopharmaceutical company. However, its business model focuses on creating shareholder value ...